Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

FDA Cancels Meeting to Review Lilly’s Cymbalta

By Pharmaceutical Processing | January 6, 2010

WASHINGTON (AP) — The Food and Drug Administration has canceled a meeting to review Eli Lilly & Co.’s antidepressant Cymbalta for a new use against chronic pain. The agency said in a statement Tuesday that the Jan. 28 meeting was canceled “to allow time for the FDA to review new information,” about the proposed use. Lilly shares fell 82 cents, or 2.3 percent, to $35 in afternoon trading. Calls placed to Lilly Tuesday were not immediately returned. The company is based in Indianapolis. Lilly withdrew an application in November 2008 after FDA reviewers questioned the methodology and dosing in some of the company’s trials. The company submitted a new application last summer that included a study of Cymbalta for chronic pain caused by osteoarthritis, along with new data from a study of lower back pain. Cymbalta is already approved to treat depression, generalized anxiety disorder, diabetic nerve pain and the pain ailment fibromyalgia. The drug is Lilly’s second-best selling product, behind the anti-psychotic Zyprexa. Cymbalta generated $2.24 billion in sales through the first three quarters of 2009. Lilly faces the loss of patents protecting several of its top selling drugs in the next few years. The patent protecting Zyprexa, which generated more than $4 billion in 2008, expires in 2011. Cymbalta’s patent expires in 2013.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE